乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASH: Hematology

<乌鸦传媒>Sickle Cell Disease Tied to Worse COVID-19 Outcomes

Black patients seem to be at higher risk for certain COVID-19 complications, death

<乌鸦传媒>Three-Drug Regimen Reduces Myeloma Treatment Burden

Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone

<乌鸦传媒>Survival Bump With Oral AML Maintenance

Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients

<乌鸦传媒>Study: Adding Aspirin to DOAC? Better Have a Good Reason

Combination tied to marked increase in bleeding risk

<乌鸦传媒>'Off-the-Shelf' Therapy Active After CAR T-Cell Failure

Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing

<乌鸦传媒>Study Bolsters Case for Novel Xarelto Formulation for Kids

Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories

<乌鸦传媒>Cancer-VTE Trial Falls Short

High dropout rate undermines rivaroxaban prophylaxis trial

<乌鸦传媒>Chemo-Free Tx Tops Best Option in Younger CLL Patients

Improved overall survival and safety with ibrutinib-based therapy

<乌鸦传媒>Combination Regimen Extends PFS in Myeloma

Large benefit but relevance of comparator questioned

<乌鸦传媒>$2 Test Could Transform Sickle Cell Dx in Africa

May have applications in high-income countries as well

<乌鸦传媒>ASH Offers Early Look at Updated SCD Guidelines

Experts formulated >50 recommendations on sickle cell disease

<乌鸦传媒>Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies

Studies test addition of targeted agents, immunotherapy

<乌鸦传媒>Novel Therapies Offer Hope in Sickle Cell Disease

Studies explore possibility of parental donor; boosting fetal hemoglobin production

<乌鸦传媒>CAR T-Cell Responses Prove Durable in ALL, DLBCL

Two studies demonstrate long-term control in relapsed/refractory disease

<乌鸦传媒>Cutting Chemo Cycles Feasible in Younger DLBCL Patients

Patients, ages 18-60, fare well with four cycles of CHOP instead of six

<乌鸦传媒>Ibrutinib Alone Wins in Older CLL Patients

Adding rituximab offered no added benefit

<乌鸦传媒>Sneak Peek at Practice-Changing Research From ASH 2018

"Big trials, big results," plus sickle cell disease and CAR T-cell therapies

<乌鸦传媒>Mixed Results with Regimens for Older AML Patients

Positive data with venetoclax, liposomal cytarabine-daunorubicin

<乌鸦传媒>Amyloidosis Treatments Miss the Heart of the Problem

Only modest improvement in end organ function

<乌鸦传媒>Bangladesh-Boston Collaborate on ASCT Center

Two dozen patients undergo successful stem cell transplant in Dhaka

<乌鸦传媒>Can Patients With Stable CML Stop Drug Therapy?

Studies examine TKI cessation and dose reduction

<乌鸦传媒>Survival Boost With Liposomal Tx in Older AML Patients

Agent may also provide a bridge to successful transplant

<乌鸦传媒>Novel Sickle Cell Tx Shows Promise for Pain Crises

Monoclonal antibody tied to lower incidence of adverse events

<乌鸦传媒>OncoBlog: Driving the CAR to a Cancer Cure?

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the "next big thing" in oncology? Presentations and discussion at a recent conference suggest the technology has considerable promise -- but will it qualify as a breakthrough? OncoBlog is a blog by the Medpage Today staff for readers with an interest in oncology. This post comes from Charles Bankhead.

<乌鸦传媒>Gene Therapy Works in SCID With No Risk of Leukemia

NEW ORLEANS -- Genetic therapy appeared to restore the immune system of patients with X-linked severe combined immunodeficiency (SCID), but without leading to leukemia as a side effect, researchers reported here.

<乌鸦传媒>Infection High in Myeloma, with High Mortality

ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here.

<乌鸦传媒>Oral Azacitidine Safe, Effective in Low-Risk MDS

ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here.

<乌鸦传媒>New Combo Replaces CHOP for Lymphoma

ATLANTA - The combination chemotherapy known as CHOP, used for nonHodgkin's lymphoma, is rapidly being replaced by bendamustine (Treanda), frequently combined with rituximab (Rituxan), researchers reported.

<乌鸦传媒>Children OK with Long-Term Exjade

ATLANTA -- Children with thalassemia and treated with the anti-iron overload drug deferasirox (Exjade) appear to tolerate the treatment for at least as long as 3 years while serum iron levels fell, researchers said here.

<乌鸦传媒>Extended Apixaban Stops VTE Recurrence

ATLANTA -- Apixaban taken for an additional year after standard venous thromboembolism (VTE) treatment reduced recurrent events in a placebo-controlled trial, researchers said.

<乌鸦传媒>Polycythemia Vera Better with Low Hematocrit

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events.

<乌鸦传媒>ASH: Drugs Effective in Chronic ITP Not Appropriate as First-Line Treatment

SAN FRANCISCO -- Rituximab (Rituxan) and eltrombopag (Promacta) are "too aggressive and too expensive" for use as first-line therapies against chronic idiopathic thrombocytopenic purpura, agreed participants in an exclusive 乌鸦传媒 roundtable discussion.